- Home
- SJT vs MOLN Comparison
SJT vs MOLN Comparison
Compare SJT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- MOLN
- Stock Information
- Founded
- SJT 1980
- MOLN 2004
- Country
- SJT United States
- MOLN Switzerland
- Employees
- SJT N/A
- MOLN N/A
- Industry
- SJT Oil & Gas Production
- MOLN
- Sector
- SJT Energy
- MOLN
- Exchange
- SJT Nasdaq
- MOLN Nasdaq
- Market Cap
- SJT 269.4M
- MOLN 142.6M
- IPO Year
- SJT N/A
- MOLN 2021
- Fundamental
- Price
- SJT $5.75
- MOLN $3.73
- Analyst Decision
- SJT
- MOLN Hold
- Analyst Count
- SJT 0
- MOLN 1
- Target Price
- SJT N/A
- MOLN $4.00
- AVG Volume (30 Days)
- SJT 196.3K
- MOLN 5.2K
- Earning Date
- SJT 11-13-2025
- MOLN 11-05-2025
- Dividend Yield
- SJT N/A
- MOLN N/A
- EPS Growth
- SJT N/A
- MOLN N/A
- EPS
- SJT N/A
- MOLN N/A
- Revenue
- SJT $42,635.00
- MOLN $856,302.00
- Revenue This Year
- SJT N/A
- MOLN N/A
- Revenue Next Year
- SJT N/A
- MOLN $1,000.00
- P/E Ratio
- SJT N/A
- MOLN N/A
- Revenue Growth
- SJT N/A
- MOLN N/A
- 52 Week Low
- SJT $3.36
- MOLN $3.36
- 52 Week High
- SJT $7.22
- MOLN $7.60
- Technical
- Relative Strength Index (RSI)
- SJT 45.22
- MOLN 51.20
- Support Level
- SJT $5.73
- MOLN $3.69
- Resistance Level
- SJT $5.91
- MOLN $3.79
- Average True Range (ATR)
- SJT 0.11
- MOLN 0.13
- MACD
- SJT 0.01
- MOLN 0.01
- Stochastic Oscillator
- SJT 25.00
- MOLN 34.55
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.